Portugal
Ophiomics, founded in 2015 and headquartered in Portugal, is at the forefront of innovation in the Biotechnology and Health Care industries, focusing on Precision Medicine solutions. Their mission is to revolutionize liver healthcare through the integration of AI and genomics, delivering transformative diagnostic solutions.
Ophiomics distinguishes itself as an end-to-end player in precision liver care, starting from biomarker discovery to algorithm development, and moving through assay prototyping and manufacturing in their ISO13485-certified facility. They specialize in clinical decision-support algorithms powered by data from genomic-based diagnostic kits analyzing both liquid and tissue biopsies.
Their modular lab platform allows for efficient innovation scaling, supporting the development of next-generation tests, including those for early liver cancer detection. With a CE-marked product in early adoption, Ophiomics continues to drive the shift towards personalized, data-driven care.
The company’s latest investment was a Venture Round in October 2019 from the European Innovation Council, fueling their continued research and development efforts.
